New Delhi, Jun 17 (PTI) Drug major Cipla has inked a pactwith Russia's
National Immunobiological Company to collaborateon HIV and Hepatitis C
drugs, entailing an investment of 2.8billion roubles (around Rs 289
crore).
The companies have inked a Memorandum of Understanding oninnovative antiviral medical products for HIV and Hepatitis Ctreatment and on technology transfer and active pharmaceuticalingredients (API) manufacturing, Cipla Ltd said in astatement.
"Today patients undergoing anti-HIV treatment have totake a lot of drugs every day. Our preparations will meet theexpectations of Russian patients and will solve this problem,"Nacimbio CEO Nikolay Semenov said.
In 2017, the company will finalise construction andvalidation of the manufacturing plant together with Cipla andproducts will be commercially available in 2018, he added.
Total investment in the project will be over 2.8 billionroubles, Semenov said.
"Currently there is no technology for full-cyclemanufacturing of HIV treatment drugs in Russia," said SubhanuSaxena, MD & Global CEO, Cipla Ltd.
"We are glad that, as a responsible partner together withNacimbio we will be able to improve drug availability forpatients and make our contribution to the fight against HIV,"he added.
National Immunobiological Company (NIC) is a holdingcompany that focuses on the development, production, anddelivery of immunobiological medicine to customers to helpprotect the population of the Russian Federation againstvarious infectious pathogens. PTI MSSMR
The companies have inked a Memorandum of Understanding oninnovative antiviral medical products for HIV and Hepatitis Ctreatment and on technology transfer and active pharmaceuticalingredients (API) manufacturing, Cipla Ltd said in astatement.
"Today patients undergoing anti-HIV treatment have totake a lot of drugs every day. Our preparations will meet theexpectations of Russian patients and will solve this problem,"Nacimbio CEO Nikolay Semenov said.
In 2017, the company will finalise construction andvalidation of the manufacturing plant together with Cipla andproducts will be commercially available in 2018, he added.
Total investment in the project will be over 2.8 billionroubles, Semenov said.
"Currently there is no technology for full-cyclemanufacturing of HIV treatment drugs in Russia," said SubhanuSaxena, MD & Global CEO, Cipla Ltd.
"We are glad that, as a responsible partner together withNacimbio we will be able to improve drug availability forpatients and make our contribution to the fight against HIV,"he added.
National Immunobiological Company (NIC) is a holdingcompany that focuses on the development, production, anddelivery of immunobiological medicine to customers to helpprotect the population of the Russian Federation againstvarious infectious pathogens. PTI MSSMR
No comments:
Post a Comment